Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China's Renhuang Pharmaceuticals has submitted an application for its Ribavirin injection to be approved in its domestic market.
Subscribe to our email newsletter
Ribavirin is an anti-viral drug which is active against a number of DNA and RNA viruses. It is used in the treatment of influenzas, flaviviruses and agents of many viral hemorrhagic fevers.
The company has finished the entire research work, including research on technology, quality, middle-testing, and stability study. Renhuang company anticipates receiving approval at the end of 2007.
“The success of the project and the approval of this product will broaden and enhance the company's product line and lay a solid foundation for Renhuang to further develop and manufacture the injection products,” commented Shaoming Li, chairman of Renhuang.